Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cartilage, Articular | 122 | 2023 | 550 | 27.510 |
Why?
|
Knee Joint | 146 | 2023 | 827 | 23.420 |
Why?
|
Menisci, Tibial | 69 | 2023 | 187 | 20.490 |
Why?
|
Knee Injuries | 75 | 2022 | 238 | 17.430 |
Why?
|
Osteoarthritis, Knee | 56 | 2022 | 400 | 13.870 |
Why?
|
Arthroscopy | 144 | 2023 | 892 | 13.790 |
Why?
|
Platelet-Rich Plasma | 43 | 2023 | 86 | 12.940 |
Why?
|
Cartilage Diseases | 39 | 2023 | 90 | 12.710 |
Why?
|
Rotator Cuff Injuries | 57 | 2023 | 298 | 11.730 |
Why?
|
Shoulder Joint | 96 | 2023 | 606 | 10.810 |
Why?
|
Anterior Cruciate Ligament Reconstruction | 60 | 2023 | 245 | 10.330 |
Why?
|
Bone Transplantation | 41 | 2023 | 234 | 10.250 |
Why?
|
Rotator Cuff | 55 | 2023 | 283 | 10.160 |
Why?
|
Osteotomy | 29 | 2022 | 171 | 9.100 |
Why?
|
Allografts | 52 | 2023 | 202 | 9.000 |
Why?
|
Tibial Meniscus Injuries | 37 | 2022 | 98 | 9.000 |
Why?
|
Humans | 541 | 2023 | 31073 | 8.600 |
Why?
|
Anterior Cruciate Ligament Injuries | 52 | 2023 | 274 | 8.460 |
Why?
|
Orthopedic Procedures | 47 | 2021 | 329 | 8.380 |
Why?
|
Transplantation, Homologous | 69 | 2023 | 296 | 7.990 |
Why?
|
Chondrocytes | 45 | 2022 | 208 | 7.050 |
Why?
|
Cartilage | 29 | 2021 | 159 | 6.990 |
Why?
|
Tibia | 34 | 2022 | 274 | 6.370 |
Why?
|
Patient Reported Outcome Measures | 51 | 2023 | 434 | 6.270 |
Why?
|
Joint Instability | 50 | 2023 | 405 | 6.260 |
Why?
|
Adult | 211 | 2023 | 8950 | 6.020 |
Why?
|
Treatment Outcome | 145 | 2023 | 3810 | 5.930 |
Why?
|
Return to Sport | 21 | 2021 | 132 | 5.670 |
Why?
|
Biological Products | 10 | 2023 | 46 | 5.630 |
Why?
|
Femur | 36 | 2022 | 402 | 5.420 |
Why?
|
Male | 253 | 2023 | 16499 | 5.350 |
Why?
|
Reoperation | 60 | 2022 | 952 | 5.180 |
Why?
|
Tendon Injuries | 26 | 2022 | 205 | 5.080 |
Why?
|
Female | 232 | 2023 | 17017 | 4.930 |
Why?
|
Young Adult | 93 | 2023 | 2061 | 4.850 |
Why?
|
Middle Aged | 181 | 2022 | 10240 | 4.600 |
Why?
|
Return to Work | 12 | 2021 | 53 | 4.500 |
Why?
|
Osteoarthritis | 26 | 2023 | 384 | 4.500 |
Why?
|
Shoulder | 34 | 2022 | 167 | 4.490 |
Why?
|
Follow-Up Studies | 73 | 2023 | 1935 | 4.470 |
Why?
|
Adolescent | 91 | 2023 | 2403 | 4.430 |
Why?
|
Arthroplasty | 30 | 2023 | 141 | 4.140 |
Why?
|
Arthroplasty, Subchondral | 12 | 2018 | 28 | 4.100 |
Why?
|
Retrospective Studies | 91 | 2023 | 3665 | 4.080 |
Why?
|
Anterior Cruciate Ligament | 42 | 2023 | 281 | 4.060 |
Why?
|
Athletic Injuries | 26 | 2020 | 180 | 4.050 |
Why?
|
Wound Healing | 23 | 2021 | 174 | 3.950 |
Why?
|
Tenodesis | 22 | 2023 | 157 | 3.840 |
Why?
|
Shoulder Injuries | 28 | 2022 | 143 | 3.810 |
Why?
|
Suture Techniques | 23 | 2022 | 145 | 3.760 |
Why?
|
Orthopedics | 13 | 2023 | 128 | 3.750 |
Why?
|
Transplantation, Autologous | 47 | 2023 | 198 | 3.390 |
Why?
|
Meniscus | 8 | 2023 | 21 | 3.380 |
Why?
|
Osteochondritis Dissecans | 9 | 2019 | 27 | 3.350 |
Why?
|
Patellofemoral Joint | 14 | 2023 | 61 | 3.250 |
Why?
|
Injections, Intra-Articular | 27 | 2022 | 97 | 3.170 |
Why?
|
Hyaluronic Acid | 17 | 2021 | 102 | 3.130 |
Why?
|
Minimal Clinically Important Difference | 16 | 2022 | 130 | 3.120 |
Why?
|
Pain | 26 | 2023 | 426 | 3.100 |
Why?
|
Patient Satisfaction | 22 | 2021 | 310 | 3.020 |
Why?
|
Magnetic Resonance Imaging | 35 | 2023 | 1318 | 2.940 |
Why?
|
Shoulder Dislocation | 15 | 2021 | 102 | 2.870 |
Why?
|
Suture Anchors | 15 | 2023 | 75 | 2.850 |
Why?
|
Range of Motion, Articular | 56 | 2023 | 737 | 2.760 |
Why?
|
Arthroplasty, Replacement, Knee | 14 | 2023 | 688 | 2.740 |
Why?
|
Fractures, Stress | 5 | 2021 | 24 | 2.710 |
Why?
|
Biomechanical Phenomena | 52 | 2022 | 700 | 2.650 |
Why?
|
Sports Medicine | 7 | 2022 | 43 | 2.470 |
Why?
|
Pain, Postoperative | 12 | 2022 | 334 | 2.290 |
Why?
|
Postoperative Complications | 25 | 2021 | 997 | 2.220 |
Why?
|
Arthroplasty, Replacement, Shoulder | 13 | 2022 | 188 | 2.210 |
Why?
|
Recovery of Function | 23 | 2020 | 298 | 2.180 |
Why?
|
Pain Measurement | 27 | 2022 | 489 | 2.160 |
Why?
|
Tendons | 21 | 2023 | 229 | 2.140 |
Why?
|
Joint Diseases | 10 | 2020 | 114 | 2.130 |
Why?
|
Meniscectomy | 11 | 2022 | 25 | 2.050 |
Why?
|
Anesthetics, Local | 6 | 2019 | 97 | 1.920 |
Why?
|
Cadaver | 44 | 2022 | 380 | 1.910 |
Why?
|
Humeral Head | 7 | 2021 | 29 | 1.890 |
Why?
|
Chondrogenesis | 7 | 2020 | 31 | 1.780 |
Why?
|
Ligaments, Articular | 14 | 2022 | 110 | 1.770 |
Why?
|
Prospective Studies | 36 | 2023 | 1899 | 1.740 |
Why?
|
Aged | 78 | 2021 | 10082 | 1.720 |
Why?
|
Graft Survival | 11 | 2020 | 98 | 1.670 |
Why?
|
Debridement | 18 | 2018 | 105 | 1.670 |
Why?
|
Cohort Studies | 36 | 2023 | 2046 | 1.650 |
Why?
|
Radiography | 25 | 2020 | 695 | 1.630 |
Why?
|
Postoperative Period | 22 | 2022 | 303 | 1.570 |
Why?
|
Scapula | 12 | 2020 | 84 | 1.530 |
Why?
|
Tendinopathy | 10 | 2021 | 61 | 1.480 |
Why?
|
Quality of Life | 20 | 2022 | 696 | 1.460 |
Why?
|
Bone Marrow | 9 | 2023 | 81 | 1.460 |
Why?
|
Sutures | 5 | 2021 | 46 | 1.440 |
Why?
|
Bone Screws | 8 | 2023 | 180 | 1.420 |
Why?
|
Growth Plate | 2 | 2020 | 24 | 1.420 |
Why?
|
Clinical Trials as Topic | 4 | 2020 | 331 | 1.380 |
Why?
|
Psychometrics | 4 | 2021 | 270 | 1.340 |
Why?
|
Stem Cell Transplantation | 4 | 2020 | 46 | 1.320 |
Why?
|
Physical Examination | 15 | 2019 | 118 | 1.320 |
Why?
|
Animals | 42 | 2022 | 4720 | 1.310 |
Why?
|
Tissue Engineering | 6 | 2012 | 39 | 1.290 |
Why?
|
Absorbable Implants | 6 | 2014 | 26 | 1.270 |
Why?
|
Athletes | 11 | 2022 | 78 | 1.260 |
Why?
|
Research Design | 5 | 2020 | 219 | 1.250 |
Why?
|
Activities of Daily Living | 12 | 2022 | 551 | 1.250 |
Why?
|
Treatment Failure | 15 | 2020 | 168 | 1.240 |
Why?
|
United States | 31 | 2021 | 2376 | 1.210 |
Why?
|
Muscle, Skeletal | 17 | 2022 | 370 | 1.190 |
Why?
|
Tomography, X-Ray Computed | 18 | 2020 | 818 | 1.190 |
Why?
|
Adrenal Cortex Hormones | 6 | 2021 | 109 | 1.190 |
Why?
|
Intra-Articular Fractures | 5 | 2020 | 16 | 1.170 |
Why?
|
Time Factors | 25 | 2021 | 1680 | 1.150 |
Why?
|
Bone Malalignment | 3 | 2016 | 20 | 1.130 |
Why?
|
Upper Extremity | 9 | 2021 | 52 | 1.120 |
Why?
|
Quality Improvement | 3 | 2019 | 165 | 1.100 |
Why?
|
Autografts | 9 | 2023 | 35 | 1.090 |
Why?
|
Patient Selection | 10 | 2020 | 246 | 1.080 |
Why?
|
Tissue Transplantation | 6 | 2016 | 19 | 1.060 |
Why?
|
Baseball | 10 | 2017 | 108 | 1.050 |
Why?
|
Postoperative Care | 11 | 2020 | 132 | 1.040 |
Why?
|
Viscosupplementation | 4 | 2020 | 8 | 1.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2018 | 190 | 1.040 |
Why?
|
Patella | 11 | 2022 | 88 | 1.030 |
Why?
|
Viscosupplements | 4 | 2020 | 11 | 1.020 |
Why?
|
Imaging, Three-Dimensional | 14 | 2020 | 230 | 1.020 |
Why?
|
Hyaline Cartilage | 6 | 2020 | 15 | 0.980 |
Why?
|
Bupivacaine | 3 | 2012 | 57 | 0.970 |
Why?
|
Arthralgia | 11 | 2020 | 133 | 0.960 |
Why?
|
Surgeons | 3 | 2021 | 87 | 0.950 |
Why?
|
Bone and Bones | 5 | 2018 | 126 | 0.930 |
Why?
|
Reproducibility of Results | 13 | 2021 | 820 | 0.920 |
Why?
|
Surveys and Questionnaires | 19 | 2020 | 1209 | 0.920 |
Why?
|
Preoperative Period | 6 | 2020 | 76 | 0.900 |
Why?
|
Recurrence | 16 | 2021 | 375 | 0.900 |
Why?
|
Musculoskeletal Diseases | 2 | 2023 | 44 | 0.890 |
Why?
|
X-Ray Microtomography | 4 | 2021 | 81 | 0.890 |
Why?
|
Computer Simulation | 10 | 2022 | 222 | 0.880 |
Why?
|
Fibrin Tissue Adhesive | 4 | 2022 | 8 | 0.880 |
Why?
|
Glenoid Cavity | 5 | 2015 | 36 | 0.880 |
Why?
|
Intercellular Signaling Peptides and Proteins | 4 | 2013 | 60 | 0.870 |
Why?
|
Humerus | 10 | 2019 | 103 | 0.870 |
Why?
|
Hemiarthroplasty | 4 | 2022 | 31 | 0.870 |
Why?
|
Writing | 1 | 2023 | 22 | 0.850 |
Why?
|
Orthopedic Surgeons | 3 | 2021 | 29 | 0.840 |
Why?
|
Ossification, Heterotopic | 2 | 2022 | 41 | 0.840 |
Why?
|
Artificial Intelligence | 1 | 2023 | 33 | 0.820 |
Why?
|
Elbow Joint | 7 | 2015 | 133 | 0.810 |
Why?
|
Extracellular Matrix | 2 | 2021 | 75 | 0.810 |
Why?
|
Acromion | 6 | 2018 | 27 | 0.810 |
Why?
|
Venous Thrombosis | 2 | 2017 | 45 | 0.790 |
Why?
|
Arthritis | 5 | 2016 | 105 | 0.780 |
Why?
|
Patellar Ligament | 8 | 2023 | 56 | 0.780 |
Why?
|
Child | 14 | 2022 | 1431 | 0.770 |
Why?
|
Arm | 9 | 2022 | 82 | 0.750 |
Why?
|
Incidence | 11 | 2019 | 790 | 0.750 |
Why?
|
Anesthesia, Dental | 2 | 2019 | 2 | 0.750 |
Why?
|
Surgical Wound | 1 | 2021 | 12 | 0.740 |
Why?
|
Soft Tissue Injuries | 3 | 2016 | 18 | 0.740 |
Why?
|
Double-Blind Method | 7 | 2022 | 499 | 0.730 |
Why?
|
Databases, Factual | 9 | 2019 | 354 | 0.730 |
Why?
|
Amnion | 2 | 2020 | 4 | 0.710 |
Why?
|
Cell Separation | 1 | 2020 | 43 | 0.700 |
Why?
|
Carticaine | 1 | 2019 | 1 | 0.700 |
Why?
|
Exercise Therapy | 4 | 2017 | 113 | 0.690 |
Why?
|
Stem Cells | 1 | 2020 | 49 | 0.690 |
Why?
|
Genu Varum | 1 | 2019 | 3 | 0.680 |
Why?
|
Basketball | 3 | 2016 | 10 | 0.680 |
Why?
|
Pulmonary Embolism | 2 | 2018 | 64 | 0.680 |
Why?
|
Rupture | 14 | 2021 | 121 | 0.680 |
Why?
|
Risk Factors | 21 | 2020 | 2591 | 0.670 |
Why?
|
Cumulative Trauma Disorders | 3 | 2017 | 17 | 0.660 |
Why?
|
Leukocytes | 3 | 2016 | 46 | 0.660 |
Why?
|
Muscle Strength | 5 | 2017 | 136 | 0.650 |
Why?
|
Shoulder Pain | 5 | 2017 | 61 | 0.650 |
Why?
|
Nerve Block | 1 | 2019 | 65 | 0.640 |
Why?
|
Age Factors | 15 | 2021 | 875 | 0.640 |
Why?
|
Catheter Ablation | 4 | 2008 | 106 | 0.620 |
Why?
|
Patient Outcome Assessment | 5 | 2018 | 44 | 0.620 |
Why?
|
Patellofemoral Pain Syndrome | 2 | 2017 | 3 | 0.620 |
Why?
|
Proteoglycans | 10 | 2022 | 345 | 0.610 |
Why?
|
Serum Albumin, Human | 1 | 2017 | 1 | 0.610 |
Why?
|
Stifle | 1 | 2018 | 12 | 0.600 |
Why?
|
Football | 5 | 2018 | 37 | 0.600 |
Why?
|
Evidence-Based Medicine | 8 | 2020 | 216 | 0.600 |
Why?
|
Practice Patterns, Physicians' | 4 | 2015 | 135 | 0.570 |
Why?
|
Regeneration | 3 | 2011 | 27 | 0.570 |
Why?
|
Randomized Controlled Trials as Topic | 14 | 2022 | 360 | 0.560 |
Why?
|
Bone Morphogenetic Proteins | 4 | 2011 | 105 | 0.560 |
Why?
|
Health Literacy | 1 | 2018 | 108 | 0.560 |
Why?
|
Patient Preference | 1 | 2017 | 37 | 0.560 |
Why?
|
Soccer | 3 | 2018 | 21 | 0.560 |
Why?
|
Synovial Fluid | 2 | 2017 | 127 | 0.560 |
Why?
|
Workers' Compensation | 6 | 2021 | 65 | 0.560 |
Why?
|
Physical Therapy Modalities | 6 | 2019 | 78 | 0.550 |
Why?
|
Prognosis | 10 | 2019 | 924 | 0.550 |
Why?
|
Stress, Mechanical | 9 | 2020 | 173 | 0.550 |
Why?
|
Clinical Decision-Making | 1 | 2016 | 43 | 0.550 |
Why?
|
Sodium Chloride | 1 | 2016 | 38 | 0.550 |
Why?
|
Second-Look Surgery | 5 | 2020 | 13 | 0.550 |
Why?
|
Lidocaine | 3 | 2019 | 44 | 0.540 |
Why?
|
Bone-Patellar Tendon-Bone Grafting | 8 | 2023 | 46 | 0.540 |
Why?
|
Hamstring Muscles | 1 | 2016 | 14 | 0.530 |
Why?
|
Cytokines | 7 | 2018 | 351 | 0.530 |
Why?
|
Patient Education as Topic | 2 | 2017 | 161 | 0.530 |
Why?
|
Lysholm Knee Score | 4 | 2021 | 8 | 0.530 |
Why?
|
Weight-Bearing | 9 | 2018 | 170 | 0.520 |
Why?
|
Time-to-Treatment | 2 | 2015 | 37 | 0.520 |
Why?
|
Prostheses and Implants | 5 | 2008 | 171 | 0.510 |
Why?
|
Tenotomy | 1 | 2015 | 16 | 0.510 |
Why?
|
Quadriceps Muscle | 4 | 2020 | 32 | 0.510 |
Why?
|
Tissue Donors | 3 | 2019 | 81 | 0.500 |
Why?
|
Tissue Adhesives | 2 | 2019 | 8 | 0.500 |
Why?
|
Knee Prosthesis | 2 | 2016 | 240 | 0.500 |
Why?
|
Multivariate Analysis | 10 | 2021 | 344 | 0.500 |
Why?
|
Sterilization | 2 | 2014 | 10 | 0.490 |
Why?
|
Analgesics, Opioid | 4 | 2022 | 226 | 0.490 |
Why?
|
Ontario | 3 | 2020 | 19 | 0.480 |
Why?
|
Cell Survival | 10 | 2020 | 164 | 0.470 |
Why?
|
Transforming Growth Factor beta | 3 | 2008 | 124 | 0.470 |
Why?
|
Serial Publications | 1 | 2014 | 1 | 0.470 |
Why?
|
Aged, 80 and over | 20 | 2018 | 5197 | 0.470 |
Why?
|
Collateral Ligaments | 2 | 2013 | 27 | 0.460 |
Why?
|
Osteochondritis | 2 | 2011 | 4 | 0.460 |
Why?
|
Cryopreservation | 2 | 2018 | 28 | 0.460 |
Why?
|
Cost-Benefit Analysis | 5 | 2022 | 149 | 0.460 |
Why?
|
Case-Control Studies | 9 | 2020 | 664 | 0.450 |
Why?
|
Anti-Infective Agents, Local | 1 | 2014 | 53 | 0.450 |
Why?
|
Chlorhexidine | 1 | 2014 | 61 | 0.440 |
Why?
|
Athletic Performance | 4 | 2020 | 18 | 0.440 |
Why?
|
Disease Models, Animal | 9 | 2021 | 782 | 0.440 |
Why?
|
Gymnastics | 2 | 2010 | 4 | 0.440 |
Why?
|
Rabbits | 7 | 2015 | 286 | 0.430 |
Why?
|
Sex Factors | 6 | 2019 | 510 | 0.420 |
Why?
|
Drug Therapy, Combination | 2 | 2011 | 246 | 0.410 |
Why?
|
Random Allocation | 9 | 2019 | 147 | 0.400 |
Why?
|
Tissue and Organ Harvesting | 4 | 2005 | 18 | 0.400 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2011 | 69 | 0.390 |
Why?
|
Cells, Cultured | 5 | 2020 | 686 | 0.380 |
Why?
|
Clinical Competence | 3 | 2019 | 241 | 0.370 |
Why?
|
Pilot Projects | 6 | 2019 | 428 | 0.370 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2022 | 105 | 0.370 |
Why?
|
Algorithms | 6 | 2020 | 416 | 0.360 |
Why?
|
Therapeutic Irrigation | 5 | 2013 | 71 | 0.360 |
Why?
|
Anti-Inflammatory Agents | 3 | 2014 | 103 | 0.360 |
Why?
|
Rotation | 12 | 2018 | 142 | 0.360 |
Why?
|
Ulna | 1 | 2010 | 29 | 0.350 |
Why?
|
Contraindications, Procedure | 2 | 2020 | 3 | 0.350 |
Why?
|
Cattle | 8 | 2019 | 220 | 0.350 |
Why?
|
Biocompatible Materials | 6 | 2016 | 105 | 0.350 |
Why?
|
Arthroplasty, Replacement | 5 | 2014 | 150 | 0.350 |
Why?
|
Fractures, Cartilage | 1 | 2010 | 5 | 0.350 |
Why?
|
Tendon Transfer | 3 | 2015 | 24 | 0.350 |
Why?
|
Models, Animal | 6 | 2015 | 130 | 0.340 |
Why?
|
Minimally Invasive Surgical Procedures | 2 | 2010 | 306 | 0.330 |
Why?
|
Fibrocartilage | 2 | 2015 | 11 | 0.330 |
Why?
|
Methylprednisolone | 1 | 2009 | 24 | 0.330 |
Why?
|
Demography | 2 | 2019 | 81 | 0.320 |
Why?
|
Child, Preschool | 3 | 2021 | 691 | 0.320 |
Why?
|
Hemostasis, Surgical | 2 | 2006 | 15 | 0.320 |
Why?
|
Survivorship | 3 | 2023 | 19 | 0.320 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 190 | 0.320 |
Why?
|
Brachial Plexus | 1 | 2008 | 5 | 0.310 |
Why?
|
Rats | 5 | 2020 | 871 | 0.310 |
Why?
|
Wounds and Injuries | 4 | 2019 | 43 | 0.310 |
Why?
|
Decompression, Surgical | 2 | 2012 | 151 | 0.310 |
Why?
|
Lower Extremity Deformities, Congenital | 1 | 2008 | 1 | 0.310 |
Why?
|
Freezing | 1 | 2008 | 15 | 0.300 |
Why?
|
Simulation Training | 2 | 2019 | 43 | 0.300 |
Why?
|
Conflict of Interest | 2 | 2019 | 18 | 0.300 |
Why?
|
Patient Positioning | 2 | 2020 | 41 | 0.300 |
Why?
|
Graft Rejection | 5 | 2014 | 75 | 0.300 |
Why?
|
Patient Care Planning | 2 | 2005 | 59 | 0.290 |
Why?
|
Lower Extremity | 2 | 2018 | 40 | 0.290 |
Why?
|
Transcutaneous Electric Nerve Stimulation | 1 | 2007 | 3 | 0.290 |
Why?
|
Physician Incentive Plans | 1 | 2007 | 2 | 0.290 |
Why?
|
Salaries and Fringe Benefits | 1 | 2007 | 12 | 0.290 |
Why?
|
Tissue Scaffolds | 3 | 2015 | 24 | 0.290 |
Why?
|
Electric Stimulation | 1 | 2007 | 83 | 0.290 |
Why?
|
Patellar Dislocation | 2 | 2019 | 23 | 0.280 |
Why?
|
Analgesia, Patient-Controlled | 2 | 2006 | 29 | 0.280 |
Why?
|
Prosthesis Failure | 2 | 2014 | 541 | 0.280 |
Why?
|
Decision Making | 2 | 2011 | 236 | 0.280 |
Why?
|
Information Systems | 3 | 2021 | 23 | 0.280 |
Why?
|
Severity of Illness Index | 7 | 2020 | 1134 | 0.280 |
Why?
|
Preoperative Care | 4 | 2020 | 144 | 0.270 |
Why?
|
Bone Resorption | 2 | 2019 | 97 | 0.270 |
Why?
|
Depression | 2 | 2021 | 481 | 0.270 |
Why?
|
Physicians | 3 | 2019 | 119 | 0.270 |
Why?
|
Models, Anatomic | 3 | 2013 | 54 | 0.270 |
Why?
|
Visual Analog Scale | 3 | 2020 | 60 | 0.270 |
Why?
|
Patient Readmission | 2 | 2018 | 132 | 0.260 |
Why?
|
Ankle Joint | 2 | 2019 | 42 | 0.260 |
Why?
|
Academic Medical Centers | 1 | 2007 | 156 | 0.260 |
Why?
|
Foreign-Body Migration | 1 | 2006 | 23 | 0.260 |
Why?
|
Organ Preservation | 1 | 2005 | 6 | 0.260 |
Why?
|
Pain Management | 1 | 2007 | 144 | 0.260 |
Why?
|
Tennis Elbow | 2 | 2019 | 13 | 0.250 |
Why?
|
Bursa, Synovial | 1 | 2005 | 10 | 0.250 |
Why?
|
Analysis of Variance | 7 | 2011 | 326 | 0.250 |
Why?
|
Electrocoagulation | 1 | 2005 | 19 | 0.250 |
Why?
|
Single-Blind Method | 5 | 2008 | 120 | 0.250 |
Why?
|
Sensitivity and Specificity | 5 | 2014 | 586 | 0.250 |
Why?
|
Burns | 1 | 2005 | 23 | 0.250 |
Why?
|
Cell Transplantation | 3 | 2010 | 27 | 0.250 |
Why?
|
Materials Testing | 4 | 2017 | 135 | 0.250 |
Why?
|
Connective Tissue | 3 | 2013 | 26 | 0.250 |
Why?
|
Collagen Type III | 3 | 2015 | 14 | 0.240 |
Why?
|
Collagen Type I | 3 | 2015 | 22 | 0.240 |
Why?
|
Disease Progression | 3 | 2016 | 833 | 0.240 |
Why?
|
Contraindications | 2 | 2016 | 42 | 0.240 |
Why?
|
Shoulder Impingement Syndrome | 3 | 2014 | 13 | 0.240 |
Why?
|
Equipment Design | 5 | 2017 | 189 | 0.240 |
Why?
|
Posterior Cruciate Ligament | 3 | 2020 | 24 | 0.240 |
Why?
|
Ambulatory Surgical Procedures | 4 | 2016 | 77 | 0.230 |
Why?
|
Health Care Surveys | 2 | 2014 | 68 | 0.230 |
Why?
|
Chondromalacia Patellae | 3 | 2009 | 4 | 0.230 |
Why?
|
Rheumatic Diseases | 1 | 2005 | 56 | 0.230 |
Why?
|
Pectoralis Muscles | 2 | 2015 | 18 | 0.230 |
Why?
|
Biomarkers | 2 | 2020 | 734 | 0.220 |
Why?
|
Prevalence | 4 | 2015 | 499 | 0.220 |
Why?
|
Risk Assessment | 6 | 2017 | 718 | 0.220 |
Why?
|
Pressure | 6 | 2015 | 64 | 0.220 |
Why?
|
Meta-Analysis as Topic | 7 | 2020 | 43 | 0.220 |
Why?
|
Casts, Surgical | 1 | 2003 | 8 | 0.220 |
Why?
|
Occlusive Dressings | 1 | 2003 | 2 | 0.220 |
Why?
|
Lacerations | 2 | 2013 | 18 | 0.210 |
Why?
|
Regression Analysis | 4 | 2014 | 301 | 0.210 |
Why?
|
Surgical Wound Infection | 2 | 2018 | 103 | 0.210 |
Why?
|
Survival Rate | 3 | 2021 | 407 | 0.210 |
Why?
|
Osteolysis | 2 | 2016 | 147 | 0.210 |
Why?
|
Mesenchymal Stem Cell Transplantation | 2 | 2020 | 35 | 0.210 |
Why?
|
Patient Care | 1 | 2023 | 34 | 0.210 |
Why?
|
Health Surveys | 2 | 2021 | 99 | 0.210 |
Why?
|
Aggrecans | 3 | 2019 | 157 | 0.210 |
Why?
|
Knee | 4 | 2020 | 47 | 0.210 |
Why?
|
Joint Dislocations | 4 | 2019 | 60 | 0.210 |
Why?
|
Publishing | 1 | 2023 | 42 | 0.210 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2022 | 32 | 0.210 |
Why?
|
Synovial Membrane | 3 | 2013 | 84 | 0.200 |
Why?
|
Practice Guidelines as Topic | 2 | 2015 | 344 | 0.200 |
Why?
|
Retinal Degeneration | 1 | 2021 | 4 | 0.200 |
Why?
|
Health Status Indicators | 3 | 2012 | 78 | 0.200 |
Why?
|
Radio Waves | 4 | 2008 | 9 | 0.200 |
Why?
|
Placenta | 1 | 2021 | 14 | 0.190 |
Why?
|
Creatine | 1 | 2021 | 4 | 0.190 |
Why?
|
Neurosurgical Procedures | 1 | 2023 | 162 | 0.190 |
Why?
|
Electromyography | 3 | 2016 | 78 | 0.190 |
Why?
|
Collagen | 4 | 2013 | 104 | 0.190 |
Why?
|
Pregnancy | 2 | 2021 | 404 | 0.190 |
Why?
|
Private Practice | 2 | 2014 | 6 | 0.190 |
Why?
|
Amniotic Fluid | 1 | 2020 | 5 | 0.190 |
Why?
|
Polymers | 4 | 2019 | 42 | 0.190 |
Why?
|
Dermatologic Surgical Procedures | 1 | 2021 | 13 | 0.190 |
Why?
|
Body Mass Index | 4 | 2020 | 453 | 0.180 |
Why?
|
Dermis | 1 | 2020 | 7 | 0.180 |
Why?
|
Internship and Residency | 3 | 2021 | 227 | 0.180 |
Why?
|
Models, Biological | 3 | 2019 | 346 | 0.180 |
Why?
|
Practice Management, Medical | 1 | 2020 | 3 | 0.180 |
Why?
|
Perioperative Period | 1 | 2020 | 12 | 0.180 |
Why?
|
Diagnostic Imaging | 2 | 2015 | 90 | 0.180 |
Why?
|
Posterior Cruciate Ligament Reconstruction | 1 | 2020 | 7 | 0.180 |
Why?
|
Movement | 3 | 2018 | 137 | 0.180 |
Why?
|
Education, Medical, Graduate | 2 | 2019 | 88 | 0.180 |
Why?
|
Polycarboxylate Cement | 3 | 2010 | 8 | 0.180 |
Why?
|
Benzophenones | 3 | 2019 | 27 | 0.180 |
Why?
|
Compressive Strength | 4 | 2008 | 29 | 0.180 |
Why?
|
Research | 1 | 2020 | 54 | 0.180 |
Why?
|
Ketones | 3 | 2019 | 22 | 0.180 |
Why?
|
Primary Cell Culture | 1 | 2020 | 21 | 0.180 |
Why?
|
Cross-Sectional Studies | 6 | 2021 | 1006 | 0.180 |
Why?
|
Molar | 1 | 2019 | 1 | 0.170 |
Why?
|
Mandibular Nerve | 1 | 2019 | 5 | 0.170 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2020 | 20 | 0.170 |
Why?
|
Opioid-Related Disorders | 1 | 2021 | 48 | 0.170 |
Why?
|
Symptom Assessment | 1 | 2020 | 23 | 0.170 |
Why?
|
Bone Diseases | 2 | 2019 | 24 | 0.170 |
Why?
|
ROC Curve | 4 | 2020 | 145 | 0.170 |
Why?
|
Self Report | 3 | 2019 | 231 | 0.170 |
Why?
|
Temperature | 2 | 2018 | 75 | 0.170 |
Why?
|
Polyethylene Glycols | 3 | 2019 | 60 | 0.170 |
Why?
|
Epinephrine | 3 | 2006 | 37 | 0.170 |
Why?
|
Chronic Disease | 3 | 2012 | 534 | 0.170 |
Why?
|
Ankle | 1 | 2019 | 17 | 0.170 |
Why?
|
Consensus | 1 | 2019 | 112 | 0.170 |
Why?
|
Feasibility Studies | 1 | 2020 | 244 | 0.170 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 165 | 0.170 |
Why?
|
Infant | 1 | 2021 | 577 | 0.160 |
Why?
|
Fracture Fixation, Internal | 1 | 2019 | 75 | 0.160 |
Why?
|
Polyurethanes | 2 | 2010 | 9 | 0.160 |
Why?
|
Aging | 4 | 2022 | 1729 | 0.160 |
Why?
|
Probability | 3 | 2007 | 99 | 0.160 |
Why?
|
Statistics, Nonparametric | 2 | 2010 | 143 | 0.160 |
Why?
|
Research Subjects | 1 | 2018 | 12 | 0.160 |
Why?
|
Patients | 1 | 2019 | 33 | 0.160 |
Why?
|
Fluoroscopy | 2 | 2011 | 63 | 0.160 |
Why?
|
Betacoronavirus | 1 | 2020 | 89 | 0.160 |
Why?
|
Mental Health | 1 | 2020 | 113 | 0.160 |
Why?
|
Delivery of Health Care | 1 | 2020 | 159 | 0.160 |
Why?
|
Rotator Cuff Tear Arthropathy | 1 | 2018 | 12 | 0.160 |
Why?
|
Odds Ratio | 4 | 2020 | 293 | 0.160 |
Why?
|
Thyroidectomy | 1 | 1998 | 11 | 0.160 |
Why?
|
Propionibacterium acnes | 1 | 2018 | 9 | 0.160 |
Why?
|
Carcinoma, Papillary | 1 | 1998 | 21 | 0.160 |
Why?
|
Doxycycline | 1 | 2018 | 20 | 0.160 |
Why?
|
Blood Specimen Collection | 1 | 2018 | 12 | 0.150 |
Why?
|
Horses | 2 | 2016 | 19 | 0.150 |
Why?
|
Surgery Department, Hospital | 1 | 1998 | 5 | 0.150 |
Why?
|
Biomedical Research | 1 | 2019 | 80 | 0.150 |
Why?
|
Prospective Payment System | 1 | 1998 | 4 | 0.150 |
Why?
|
Diagnosis-Related Groups | 1 | 1998 | 10 | 0.150 |
Why?
|
Coronavirus Infections | 1 | 2020 | 101 | 0.150 |
Why?
|
Thyroid Neoplasms | 1 | 1998 | 39 | 0.150 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 104 | 0.150 |
Why?
|
Durapatite | 1 | 1997 | 10 | 0.150 |
Why?
|
Molecular Weight | 1 | 2017 | 45 | 0.150 |
Why?
|
Medical Records | 1 | 1998 | 34 | 0.150 |
Why?
|
Medical Staff, Hospital | 1 | 1998 | 20 | 0.150 |
Why?
|
Carboplatin | 1 | 1997 | 50 | 0.150 |
Why?
|
Histiocytoma, Benign Fibrous | 1 | 1997 | 5 | 0.150 |
Why?
|
Humeral Fractures | 1 | 2017 | 23 | 0.150 |
Why?
|
Pandemics | 1 | 2020 | 274 | 0.150 |
Why?
|
Extracellular Matrix Proteins | 2 | 2015 | 131 | 0.150 |
Why?
|
Paclitaxel | 1 | 1997 | 76 | 0.150 |
Why?
|
Pneumonia | 1 | 2018 | 75 | 0.150 |
Why?
|
Pyridones | 1 | 2017 | 13 | 0.150 |
Why?
|
Body Height | 3 | 2015 | 34 | 0.150 |
Why?
|
Fever | 1 | 2017 | 42 | 0.150 |
Why?
|
Education, Medical, Continuing | 2 | 2013 | 44 | 0.150 |
Why?
|
Bone Morphogenetic Protein 2 | 3 | 2012 | 47 | 0.150 |
Why?
|
Observer Variation | 3 | 2012 | 118 | 0.140 |
Why?
|
Osteoporosis | 1 | 2018 | 85 | 0.140 |
Why?
|
Gait | 2 | 2016 | 407 | 0.140 |
Why?
|
Electronic Health Records | 1 | 2017 | 70 | 0.140 |
Why?
|
Immunohistochemistry | 2 | 2008 | 430 | 0.140 |
Why?
|
Achilles Tendon | 2 | 2014 | 19 | 0.140 |
Why?
|
Disclosure | 1 | 2016 | 14 | 0.140 |
Why?
|
Soft Tissue Neoplasms | 1 | 1997 | 59 | 0.140 |
Why?
|
Tensile Strength | 3 | 2019 | 29 | 0.140 |
Why?
|
Patient Compliance | 1 | 2017 | 158 | 0.130 |
Why?
|
Brain Concussion | 1 | 2016 | 13 | 0.130 |
Why?
|
Head and Neck Neoplasms | 1 | 1997 | 144 | 0.130 |
Why?
|
Disability Evaluation | 3 | 2020 | 333 | 0.130 |
Why?
|
Orthopedic Fixation Devices | 1 | 2016 | 25 | 0.130 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1997 | 192 | 0.130 |
Why?
|
Deltoid Muscle | 1 | 2015 | 6 | 0.130 |
Why?
|
Rats, Sprague-Dawley | 2 | 2007 | 467 | 0.130 |
Why?
|
Mice | 6 | 2021 | 1681 | 0.130 |
Why?
|
Network Meta-Analysis | 3 | 2021 | 28 | 0.130 |
Why?
|
Capsaicin | 1 | 2015 | 11 | 0.130 |
Why?
|
Bone Marrow Transplantation | 2 | 2010 | 36 | 0.130 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 1997 | 337 | 0.130 |
Why?
|
Prosthesis-Related Infections | 1 | 2018 | 222 | 0.130 |
Why?
|
Arthrography | 2 | 2015 | 27 | 0.130 |
Why?
|
Thoracic Nerves | 1 | 2015 | 3 | 0.120 |
Why?
|
Mononeuropathies | 1 | 2015 | 3 | 0.120 |
Why?
|
Paralysis | 1 | 2015 | 20 | 0.120 |
Why?
|
Surgical Procedures, Operative | 2 | 2009 | 28 | 0.120 |
Why?
|
Societies, Medical | 1 | 2016 | 191 | 0.120 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 420 | 0.120 |
Why?
|
Bone-Patellar Tendon-Bone Grafts | 1 | 2014 | 4 | 0.120 |
Why?
|
Palliative Care | 2 | 2007 | 154 | 0.120 |
Why?
|
Knee Dislocation | 2 | 2005 | 7 | 0.120 |
Why?
|
Musculoskeletal System | 1 | 2014 | 6 | 0.120 |
Why?
|
Unnecessary Procedures | 1 | 2014 | 28 | 0.120 |
Why?
|
Ilium | 1 | 2014 | 34 | 0.120 |
Why?
|
New England | 1 | 2014 | 2 | 0.120 |
Why?
|
Elementary Particles | 1 | 2014 | 5 | 0.120 |
Why?
|
Quantum Theory | 1 | 2014 | 6 | 0.120 |
Why?
|
Acupuncture | 1 | 2013 | 3 | 0.120 |
Why?
|
Guided Tissue Regeneration | 1 | 2013 | 10 | 0.110 |
Why?
|
Placebos | 1 | 2014 | 79 | 0.110 |
Why?
|
Hyperthermia, Induced | 3 | 2005 | 6 | 0.110 |
Why?
|
Models, Educational | 1 | 2013 | 37 | 0.110 |
Why?
|
Elbow | 3 | 2021 | 50 | 0.110 |
Why?
|
Computer-Assisted Instruction | 1 | 2013 | 26 | 0.110 |
Why?
|
Guideline Adherence | 1 | 2014 | 68 | 0.110 |
Why?
|
Medical Records Systems, Computerized | 1 | 2013 | 12 | 0.110 |
Why?
|
Models, Theoretical | 1 | 2014 | 94 | 0.110 |
Why?
|
Primary Health Care | 1 | 2014 | 100 | 0.110 |
Why?
|
Hospitalization | 1 | 2016 | 336 | 0.110 |
Why?
|
Cross-Over Studies | 1 | 2013 | 73 | 0.110 |
Why?
|
Acromioclavicular Joint | 1 | 2013 | 19 | 0.110 |
Why?
|
Longitudinal Studies | 1 | 2017 | 1507 | 0.110 |
Why?
|
Cell Proliferation | 4 | 2019 | 204 | 0.110 |
Why?
|
ADAM Proteins | 1 | 2013 | 66 | 0.110 |
Why?
|
Reference Values | 3 | 2010 | 230 | 0.110 |
Why?
|
Cell Death | 5 | 2007 | 61 | 0.110 |
Why?
|
Bone Marrow Cells | 2 | 2020 | 59 | 0.110 |
Why?
|
Polyphenols | 1 | 2012 | 5 | 0.110 |
Why?
|
Stilbenes | 1 | 2012 | 5 | 0.110 |
Why?
|
Osteophyte | 2 | 2012 | 8 | 0.110 |
Why?
|
Fascia Lata | 2 | 2023 | 11 | 0.110 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2012 | 6 | 0.100 |
Why?
|
Chondrosarcoma | 1 | 2012 | 37 | 0.100 |
Why?
|
Microscopy, Confocal | 4 | 2007 | 118 | 0.100 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2012 | 22 | 0.100 |
Why?
|
Bone Morphogenetic Protein 7 | 2 | 2012 | 63 | 0.100 |
Why?
|
Joint Prosthesis | 1 | 2013 | 81 | 0.100 |
Why?
|
Vasoconstrictor Agents | 2 | 2003 | 31 | 0.100 |
Why?
|
Equipment Failure | 2 | 2017 | 53 | 0.100 |
Why?
|
Goats | 2 | 2009 | 10 | 0.100 |
Why?
|
Arm Injuries | 1 | 2012 | 11 | 0.100 |
Why?
|
Transforming Growth Factors | 1 | 2011 | 2 | 0.100 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2011 | 6 | 0.100 |
Why?
|
Fibroblast Growth Factors | 1 | 2011 | 8 | 0.100 |
Why?
|
Braces | 2 | 2016 | 26 | 0.100 |
Why?
|
Ceramics | 1 | 2011 | 25 | 0.100 |
Why?
|
Acute Disease | 2 | 2010 | 232 | 0.100 |
Why?
|
Synovitis | 1 | 2011 | 23 | 0.100 |
Why?
|
Osseointegration | 1 | 2012 | 77 | 0.100 |
Why?
|
Age Distribution | 3 | 2016 | 96 | 0.090 |
Why?
|
Bone Neoplasms | 1 | 2012 | 120 | 0.090 |
Why?
|
Joint Capsule Release | 1 | 2011 | 8 | 0.090 |
Why?
|
Epiphyses | 2 | 2020 | 14 | 0.090 |
Why?
|
Work Capacity Evaluation | 1 | 2010 | 8 | 0.090 |
Why?
|
Hot Temperature | 2 | 2008 | 23 | 0.090 |
Why?
|
Comorbidity | 2 | 2018 | 508 | 0.090 |
Why?
|
Resistance Training | 1 | 2010 | 9 | 0.090 |
Why?
|
Dissection | 1 | 2010 | 27 | 0.090 |
Why?
|
Machine Learning | 2 | 2021 | 63 | 0.090 |
Why?
|
Software | 2 | 2021 | 73 | 0.090 |
Why?
|
Ultrasonography, Interventional | 1 | 2011 | 70 | 0.090 |
Why?
|
Documentation | 2 | 2022 | 33 | 0.090 |
Why?
|
Transforming Growth Factor beta1 | 3 | 2015 | 32 | 0.090 |
Why?
|
Transplants | 1 | 2009 | 11 | 0.090 |
Why?
|
Hypertrophy | 1 | 2009 | 20 | 0.090 |
Why?
|
Prosthesis Fitting | 1 | 2009 | 24 | 0.080 |
Why?
|
Organ Size | 1 | 2009 | 108 | 0.080 |
Why?
|
Fallopian Tube Diseases | 1 | 2009 | 1 | 0.080 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 1997 | 862 | 0.080 |
Why?
|
Infertility, Female | 1 | 2009 | 13 | 0.080 |
Why?
|
Risk | 2 | 2020 | 223 | 0.080 |
Why?
|
Anesthetics | 1 | 2009 | 24 | 0.080 |
Why?
|
Asepsis | 1 | 2008 | 2 | 0.080 |
Why?
|
Body Weight | 1 | 2009 | 141 | 0.080 |
Why?
|
Dogs | 2 | 2008 | 264 | 0.080 |
Why?
|
Models, Statistical | 1 | 2009 | 135 | 0.080 |
Why?
|
Calcitonin Gene-Related Peptide | 1 | 2008 | 15 | 0.080 |
Why?
|
Substance P | 1 | 2008 | 18 | 0.080 |
Why?
|
Axons | 1 | 2008 | 37 | 0.080 |
Why?
|
Torque | 3 | 2017 | 27 | 0.080 |
Why?
|
Elasticity | 1 | 2008 | 40 | 0.080 |
Why?
|
Transplantation | 1 | 2008 | 5 | 0.080 |
Why?
|
Histocytochemistry | 1 | 2008 | 26 | 0.080 |
Why?
|
Horse Diseases | 1 | 2008 | 4 | 0.080 |
Why?
|
Logistic Models | 2 | 2020 | 411 | 0.080 |
Why?
|
Smoking | 3 | 2018 | 197 | 0.070 |
Why?
|
Egypt | 1 | 2007 | 3 | 0.070 |
Why?
|
Management Information Systems | 1 | 2007 | 3 | 0.070 |
Why?
|
Internal Fixators | 1 | 2007 | 53 | 0.070 |
Why?
|
Hip Joint | 1 | 2011 | 408 | 0.070 |
Why?
|
Quality-Adjusted Life Years | 3 | 2014 | 24 | 0.070 |
Why?
|
Tissue Preservation | 1 | 2006 | 6 | 0.070 |
Why?
|
Arachidonate 5-Lipoxygenase | 1 | 2006 | 8 | 0.070 |
Why?
|
Forecasting | 2 | 2005 | 115 | 0.070 |
Why?
|
Ultrasonic Therapy | 1 | 2006 | 20 | 0.070 |
Why?
|
Arachidonic Acid | 1 | 2006 | 14 | 0.070 |
Why?
|
Drug Combinations | 1 | 2006 | 68 | 0.070 |
Why?
|
Collagen Type II | 2 | 2019 | 33 | 0.070 |
Why?
|
Mechanics | 1 | 2006 | 4 | 0.070 |
Why?
|
Muscle Weakness | 1 | 2006 | 34 | 0.070 |
Why?
|
Tissue and Organ Procurement | 1 | 2006 | 35 | 0.070 |
Why?
|
Arthroscopes | 2 | 2007 | 9 | 0.070 |
Why?
|
Jogging | 1 | 2005 | 3 | 0.070 |
Why?
|
Muscular Atrophy | 1 | 2005 | 6 | 0.070 |
Why?
|
Medial Collateral Ligament, Knee | 1 | 2006 | 8 | 0.070 |
Why?
|
Cell Differentiation | 2 | 2019 | 152 | 0.060 |
Why?
|
Reactive Oxygen Species | 1 | 2006 | 132 | 0.060 |
Why?
|
Glucosamine | 1 | 2005 | 9 | 0.060 |
Why?
|
Fractures, Compression | 1 | 2005 | 8 | 0.060 |
Why?
|
Joints | 1 | 2006 | 99 | 0.060 |
Why?
|
Sulfur Radioisotopes | 1 | 2005 | 13 | 0.060 |
Why?
|
Chondroitin Sulfates | 1 | 2005 | 30 | 0.060 |
Why?
|
Sulfates | 1 | 2005 | 16 | 0.060 |
Why?
|
Education, Continuing | 1 | 2005 | 14 | 0.060 |
Why?
|
Fractures, Spontaneous | 1 | 2005 | 11 | 0.060 |
Why?
|
Equipment Safety | 1 | 2005 | 13 | 0.060 |
Why?
|
Bone Marrow Diseases | 1 | 2005 | 9 | 0.060 |
Why?
|
Osteonecrosis | 1 | 2005 | 19 | 0.060 |
Why?
|
Shoulder Fractures | 1 | 2005 | 29 | 0.060 |
Why?
|
Sex Distribution | 2 | 2016 | 90 | 0.060 |
Why?
|
Fracture Fixation | 1 | 2005 | 25 | 0.060 |
Why?
|
Arthrometry, Articular | 2 | 2017 | 15 | 0.060 |
Why?
|
Edema | 1 | 2005 | 40 | 0.060 |
Why?
|
Image Enhancement | 1 | 2005 | 60 | 0.060 |
Why?
|
Joint Capsule | 1 | 2005 | 46 | 0.060 |
Why?
|
Diet | 1 | 2006 | 194 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 135 | 0.060 |
Why?
|
Drug Administration Schedule | 1 | 2005 | 225 | 0.060 |
Why?
|
Prosthesis Design | 2 | 2019 | 509 | 0.060 |
Why?
|
Decision Support Techniques | 2 | 2014 | 52 | 0.060 |
Why?
|
Glycosaminoglycans | 2 | 2017 | 53 | 0.060 |
Why?
|
Surface Properties | 2 | 2009 | 135 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2005 | 444 | 0.060 |
Why?
|
Mice, Inbred C57BL | 2 | 2017 | 463 | 0.060 |
Why?
|
Ligaments | 1 | 2023 | 15 | 0.060 |
Why?
|
Radiostereometric Analysis | 1 | 2023 | 7 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2015 | 234 | 0.060 |
Why?
|
Medical Illustration | 2 | 2015 | 17 | 0.050 |
Why?
|
Obesity | 1 | 2006 | 307 | 0.050 |
Why?
|
Recombinant Proteins | 3 | 1999 | 256 | 0.050 |
Why?
|
Skin Temperature | 1 | 2003 | 1 | 0.050 |
Why?
|
Interleukin-1beta | 2 | 2013 | 61 | 0.050 |
Why?
|
Pulmonary Edema | 1 | 2003 | 21 | 0.050 |
Why?
|
Intraoperative Complications | 1 | 2003 | 75 | 0.050 |
Why?
|
Confidence Intervals | 3 | 2009 | 97 | 0.050 |
Why?
|
Gene Expression | 2 | 2013 | 239 | 0.050 |
Why?
|
Transplantation Immunology | 1 | 2002 | 4 | 0.050 |
Why?
|
Indazoles | 1 | 2022 | 8 | 0.050 |
Why?
|
Microscopy, Electron, Scanning | 2 | 2002 | 77 | 0.050 |
Why?
|
Automation | 1 | 2021 | 11 | 0.050 |
Why?
|
Pyridines | 1 | 2022 | 47 | 0.050 |
Why?
|
Patient Admission | 2 | 2001 | 31 | 0.050 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 44 | 0.050 |
Why?
|
Inositol | 1 | 2021 | 7 | 0.050 |
Why?
|
Rats, Inbred Lew | 2 | 1999 | 11 | 0.050 |
Why?
|
Felypressin | 1 | 2001 | 1 | 0.050 |
Why?
|
Prilocaine | 1 | 2001 | 1 | 0.050 |
Why?
|
Metabolomics | 1 | 2021 | 23 | 0.050 |
Why?
|
Fetus | 1 | 2001 | 59 | 0.050 |
Why?
|
Imidazoles | 1 | 2022 | 73 | 0.050 |
Why?
|
Lipids | 1 | 2021 | 38 | 0.050 |
Why?
|
Glucose | 1 | 2021 | 65 | 0.050 |
Why?
|
Reconstructive Surgical Procedures | 1 | 2001 | 6 | 0.050 |
Why?
|
Chorion | 1 | 2020 | 2 | 0.050 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2020 | 3 | 0.050 |
Why?
|
Umbilical Cord | 1 | 2020 | 4 | 0.050 |
Why?
|
Computers | 1 | 2021 | 27 | 0.050 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2021 | 35 | 0.050 |
Why?
|
Chromatography, Liquid | 1 | 2020 | 25 | 0.050 |
Why?
|
Registries | 2 | 2019 | 203 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2021 | 46 | 0.050 |
Why?
|
Tandem Mass Spectrometry | 1 | 2020 | 28 | 0.050 |
Why?
|
Supervised Machine Learning | 1 | 2020 | 12 | 0.050 |
Why?
|
Expert Testimony | 1 | 2020 | 12 | 0.050 |
Why?
|
Steroids | 1 | 2020 | 23 | 0.050 |
Why?
|
Area Under Curve | 1 | 2020 | 70 | 0.050 |
Why?
|
Osteogenesis | 2 | 1999 | 107 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2014 | 225 | 0.050 |
Why?
|
Survival Analysis | 2 | 1998 | 322 | 0.040 |
Why?
|
Heart Rate | 1 | 2001 | 160 | 0.040 |
Why?
|
Personal Satisfaction | 1 | 2020 | 49 | 0.040 |
Why?
|
Sports | 1 | 2020 | 47 | 0.040 |
Why?
|
Commerce | 1 | 2020 | 13 | 0.040 |
Why?
|
Inflammation | 2 | 2012 | 361 | 0.040 |
Why?
|
Proteomics | 1 | 2020 | 96 | 0.040 |
Why?
|
Elastic Modulus | 1 | 2019 | 12 | 0.040 |
Why?
|
Delphi Technique | 1 | 2019 | 30 | 0.040 |
Why?
|
Fibrinogen | 1 | 2019 | 20 | 0.040 |
Why?
|
Thrombin | 1 | 2019 | 12 | 0.040 |
Why?
|
Blood Pressure | 1 | 2001 | 262 | 0.040 |
Why?
|
Quality Assurance, Health Care | 1 | 2020 | 50 | 0.040 |
Why?
|
Rehabilitation | 1 | 2019 | 14 | 0.040 |
Why?
|
Health Care Costs | 1 | 2020 | 72 | 0.040 |
Why?
|
Morphine | 1 | 2020 | 85 | 0.040 |
Why?
|
Ultrasonography | 1 | 2001 | 271 | 0.040 |
Why?
|
Motion Therapy, Continuous Passive | 1 | 2019 | 5 | 0.040 |
Why?
|
Desiccation | 1 | 2019 | 5 | 0.040 |
Why?
|
Platelet Count | 1 | 2019 | 22 | 0.040 |
Why?
|
Immobilization | 1 | 1999 | 15 | 0.040 |
Why?
|
Medicare | 1 | 2020 | 127 | 0.040 |
Why?
|
Ischemia | 1 | 1999 | 28 | 0.040 |
Why?
|
Angiography | 1 | 1999 | 44 | 0.040 |
Why?
|
Glucocorticoids | 1 | 2019 | 71 | 0.040 |
Why?
|
Bone Density | 1 | 2019 | 152 | 0.040 |
Why?
|
Carcinoma, Papillary, Follicular | 1 | 1998 | 1 | 0.040 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2019 | 81 | 0.040 |
Why?
|
Nitric Oxide | 2 | 2009 | 103 | 0.040 |
Why?
|
Lymph Node Excision | 1 | 1998 | 27 | 0.040 |
Why?
|
Adipose Tissue | 1 | 2019 | 78 | 0.040 |
Why?
|
Carcinoma, Lobular | 1 | 1998 | 17 | 0.040 |
Why?
|
Tissue Banks | 1 | 2018 | 8 | 0.040 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 1998 | 29 | 0.040 |
Why?
|
Forms and Records Control | 1 | 1998 | 10 | 0.040 |
Why?
|
Operating Rooms | 1 | 2018 | 13 | 0.040 |
Why?
|
Interferon-beta | 1 | 1997 | 7 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 1997 | 29 | 0.040 |
Why?
|
Michigan | 1 | 2017 | 14 | 0.040 |
Why?
|
Porosity | 1 | 1997 | 68 | 0.040 |
Why?
|
Femoral Neck Fractures | 1 | 1997 | 12 | 0.040 |
Why?
|
Hyaluronan Synthases | 1 | 2017 | 8 | 0.040 |
Why?
|
Prosthesis Implantation | 1 | 1997 | 35 | 0.040 |
Why?
|
Coracoid Process | 1 | 2017 | 6 | 0.040 |
Why?
|
Fatal Outcome | 1 | 1997 | 65 | 0.040 |
Why?
|
Skin | 1 | 2018 | 124 | 0.040 |
Why?
|
Chi-Square Distribution | 1 | 1997 | 149 | 0.040 |
Why?
|
Fibrosis | 1 | 2017 | 39 | 0.040 |
Why?
|
Tarsal Bones | 1 | 2016 | 7 | 0.040 |
Why?
|
Muscle Fatigue | 1 | 2017 | 9 | 0.040 |
Why?
|
Torso | 1 | 2017 | 7 | 0.040 |
Why?
|
Computer-Aided Design | 1 | 2017 | 16 | 0.040 |
Why?
|
Interleukins | 1 | 2017 | 38 | 0.030 |
Why?
|
Industry | 1 | 2016 | 9 | 0.030 |
Why?
|
Titanium | 1 | 1997 | 196 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 1997 | 387 | 0.030 |
Why?
|
Multiple Sclerosis | 1 | 1997 | 84 | 0.030 |
Why?
|
Apoptosis | 2 | 2012 | 260 | 0.030 |
Why?
|
Online Systems | 1 | 2016 | 5 | 0.030 |
Why?
|
Early Ambulation | 1 | 2016 | 20 | 0.030 |
Why?
|
Anemia, Sickle Cell | 1 | 1996 | 13 | 0.030 |
Why?
|
Current Procedural Terminology | 1 | 2016 | 14 | 0.030 |
Why?
|
History, 21st Century | 1 | 2016 | 35 | 0.030 |
Why?
|
Proprioception | 1 | 2016 | 19 | 0.030 |
Why?
|
Epidemiologic Methods | 1 | 2016 | 20 | 0.030 |
Why?
|
History, 20th Century | 1 | 2016 | 70 | 0.030 |
Why?
|
Hypertension | 1 | 2018 | 288 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2015 | 3 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2016 | 68 | 0.030 |
Why?
|
Injury Severity Score | 1 | 2015 | 14 | 0.030 |
Why?
|
Kidney Glomerulus | 1 | 1996 | 58 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 1996 | 64 | 0.030 |
Why?
|
Photography | 1 | 2015 | 17 | 0.030 |
Why?
|
Healthy Volunteers | 1 | 2015 | 49 | 0.030 |
Why?
|
Perioperative Care | 1 | 2016 | 56 | 0.030 |
Why?
|
Program Evaluation | 1 | 2016 | 136 | 0.030 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 27 | 0.030 |
Why?
|
Video Recording | 1 | 2015 | 44 | 0.030 |
Why?
|
Rupture, Spontaneous | 1 | 2014 | 7 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2014 | 15 | 0.030 |
Why?
|
Family | 1 | 1996 | 100 | 0.030 |
Why?
|
Occupational Injuries | 1 | 2015 | 9 | 0.030 |
Why?
|
Posture | 1 | 2015 | 72 | 0.030 |
Why?
|
Immunization | 1 | 1994 | 47 | 0.030 |
Why?
|
Thorax | 1 | 2014 | 12 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2014 | 36 | 0.030 |
Why?
|
Medical History Taking | 1 | 2014 | 25 | 0.030 |
Why?
|
Global Health | 1 | 2015 | 58 | 0.030 |
Why?
|
Denmark | 1 | 2014 | 12 | 0.030 |
Why?
|
Kidney Diseases | 1 | 1996 | 123 | 0.030 |
Why?
|
Hemostatic Techniques | 1 | 2014 | 9 | 0.030 |
Why?
|
Kidney Transplantation | 1 | 1996 | 126 | 0.030 |
Why?
|
Thigh | 1 | 2014 | 32 | 0.030 |
Why?
|
Quality of Health Care | 1 | 2016 | 146 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2014 | 23 | 0.030 |
Why?
|
Mesons | 1 | 2014 | 5 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 1998 | 375 | 0.030 |
Why?
|
Electrons | 1 | 2014 | 18 | 0.030 |
Why?
|
Anti-Infective Agents | 1 | 2014 | 63 | 0.030 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2013 | 7 | 0.030 |
Why?
|
Matrix Metalloproteinase 13 | 1 | 2013 | 32 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2013 | 37 | 0.030 |
Why?
|
Learning Curve | 1 | 2013 | 19 | 0.030 |
Why?
|
Muscle Strength Dynamometer | 1 | 2013 | 18 | 0.030 |
Why?
|
Acellular Dermis | 1 | 2013 | 6 | 0.030 |
Why?
|
Physical Conditioning, Animal | 1 | 2013 | 7 | 0.030 |
Why?
|
Hip | 1 | 2013 | 44 | 0.030 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2013 | 3 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 158 | 0.030 |
Why?
|
ADAMTS5 Protein | 1 | 2013 | 30 | 0.030 |
Why?
|
Metals | 1 | 2014 | 154 | 0.030 |
Why?
|
Analgesics | 1 | 2014 | 109 | 0.030 |
Why?
|
Integrins | 1 | 2013 | 21 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2013 | 6 | 0.030 |
Why?
|
Clavicle | 1 | 2013 | 16 | 0.030 |
Why?
|
Equipment Failure Analysis | 1 | 2013 | 105 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2013 | 112 | 0.030 |
Why?
|
Surgical Instruments | 1 | 2013 | 26 | 0.030 |
Why?
|
Linear Models | 1 | 2013 | 273 | 0.030 |
Why?
|
Oncogene Protein v-akt | 1 | 2012 | 11 | 0.030 |
Why?
|
Metabolism | 1 | 2012 | 9 | 0.030 |
Why?
|
Plants | 1 | 2012 | 9 | 0.030 |
Why?
|
Peptide Hydrolases | 1 | 2012 | 14 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2012 | 17 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 28 | 0.030 |
Why?
|
CD11b Antigen | 1 | 2012 | 18 | 0.030 |
Why?
|
Neovascularization, Physiologic | 1 | 2012 | 23 | 0.030 |
Why?
|
Species Specificity | 1 | 2012 | 73 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2013 | 322 | 0.030 |
Why?
|
Artificial Cells | 1 | 2012 | 2 | 0.030 |
Why?
|
Proteins | 1 | 2012 | 73 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2012 | 81 | 0.030 |
Why?
|
Gamma Rays | 1 | 2012 | 16 | 0.030 |
Why?
|
Secondary Prevention | 1 | 2012 | 67 | 0.030 |
Why?
|
Erythrocytes | 1 | 2012 | 21 | 0.030 |
Why?
|
Blood Platelets | 1 | 2012 | 51 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2012 | 271 | 0.020 |
Why?
|
Transcription Factors | 1 | 2012 | 172 | 0.020 |
Why?
|
Device Removal | 1 | 2012 | 91 | 0.020 |
Why?
|
Coronary Disease | 1 | 1991 | 86 | 0.020 |
Why?
|
In Vitro Techniques | 2 | 2002 | 215 | 0.020 |
Why?
|
Behavior Therapy | 1 | 1991 | 79 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 286 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2012 | 274 | 0.020 |
Why?
|
Neutrophils | 1 | 2011 | 120 | 0.020 |
Why?
|
Occupations | 1 | 2010 | 14 | 0.020 |
Why?
|
Functional Laterality | 1 | 2010 | 89 | 0.020 |
Why?
|
Signal Transduction | 1 | 2012 | 498 | 0.020 |
Why?
|
Hip Prosthesis | 1 | 1995 | 579 | 0.020 |
Why?
|
Fertility Agents, Female | 1 | 2009 | 1 | 0.020 |
Why?
|
Hysterosalpingography | 1 | 2009 | 1 | 0.020 |
Why?
|
Nigeria | 1 | 2009 | 4 | 0.020 |
Why?
|
Clomiphene | 1 | 2009 | 2 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2009 | 16 | 0.020 |
Why?
|
Sheep | 1 | 2008 | 42 | 0.020 |
Why?
|
Pregnancy Complications | 1 | 2009 | 55 | 0.020 |
Why?
|
Preservation, Biological | 1 | 2008 | 4 | 0.020 |
Why?
|
Cold Temperature | 1 | 2008 | 18 | 0.020 |
Why?
|
Nitric Oxide Synthase | 1 | 2008 | 47 | 0.020 |
Why?
|
Biopsy | 1 | 2008 | 249 | 0.020 |
Why?
|
Fractures, Bone | 1 | 2007 | 81 | 0.020 |
Why?
|
Mice, SCID | 1 | 2006 | 58 | 0.020 |
Why?
|
Cell Movement | 1 | 2006 | 105 | 0.020 |
Why?
|
Minicomputers | 1 | 2005 | 1 | 0.020 |
Why?
|
Selection Bias | 1 | 2005 | 10 | 0.020 |
Why?
|
Thermography | 1 | 2005 | 13 | 0.020 |
Why?
|
Body Temperature | 1 | 2005 | 58 | 0.020 |
Why?
|
Immunoassay | 1 | 1984 | 45 | 0.010 |
Why?
|
Intraoperative Period | 1 | 2002 | 34 | 0.010 |
Why?
|
Dental Restoration, Permanent | 1 | 2001 | 1 | 0.010 |
Why?
|
Dental Care for Children | 1 | 2001 | 2 | 0.010 |
Why?
|
Hospital Charges | 1 | 2001 | 20 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2001 | 80 | 0.010 |
Why?
|
Polyglycolic Acid | 1 | 1999 | 2 | 0.010 |
Why?
|
Transplantation, Isogeneic | 1 | 1999 | 2 | 0.010 |
Why?
|
Drug Carriers | 1 | 1999 | 8 | 0.010 |
Why?
|
Lactic Acid | 1 | 1999 | 17 | 0.010 |
Why?
|
Rhode Island | 1 | 1998 | 1 | 0.010 |
Why?
|
Massachusetts | 1 | 1998 | 19 | 0.010 |
Why?
|
Axilla | 1 | 1998 | 15 | 0.010 |
Why?
|
Interferon beta-1b | 1 | 1997 | 1 | 0.010 |
Why?
|
Interferon beta-1a | 1 | 1997 | 2 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 1998 | 87 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 1998 | 104 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 1998 | 370 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 1998 | 404 | 0.010 |
Why?
|
Histocompatibility | 1 | 1996 | 3 | 0.010 |
Why?
|
HLA Antigens | 1 | 1996 | 18 | 0.010 |
Why?
|
Glomerulonephritis | 1 | 1996 | 23 | 0.010 |
Why?
|
Haplotypes | 1 | 1996 | 64 | 0.010 |
Why?
|
Equipment Reuse | 1 | 1995 | 2 | 0.010 |
Why?
|
Hospitals, Special | 1 | 1995 | 8 | 0.010 |
Why?
|
Cost Control | 1 | 1995 | 11 | 0.010 |
Why?
|
New York City | 1 | 1995 | 17 | 0.010 |
Why?
|
Stress, Physiological | 1 | 1994 | 20 | 0.010 |
Why?
|
Immunoglobulins | 1 | 1994 | 31 | 0.010 |
Why?
|
Program Development | 1 | 1995 | 73 | 0.010 |
Why?
|
Lymphocytes | 1 | 1994 | 111 | 0.010 |
Why?
|
Hypercholesterolemia | 1 | 1991 | 30 | 0.010 |
Why?
|
Reagent Kits, Diagnostic | 1 | 1984 | 19 | 0.000 |
Why?
|
Laboratories | 1 | 1984 | 26 | 0.000 |
Why?
|
Quality Control | 1 | 1984 | 47 | 0.000 |
Why?
|
Triiodothyronine | 1 | 1984 | 29 | 0.000 |
Why?
|
Thyroxine | 1 | 1984 | 27 | 0.000 |
Why?
|